

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shawn Shui-on LEUNG
Title: Framework-Patched Immunoglobulins
Appl. No.: 09/892,613
Filing Date: June 27, 2001
Examiner: David BLANCHARD
Art Unit: 1643
Atty Docket No: SBL-001US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits after the filing of a request for continued examination under § 1.114. Accordingly, no certification or fee is required.

To the extent required, copies of the cited references are enclosed herewith. However, to the extent that copies of U.S. patents and published patent applications are not required, they have not been provided.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: August 7, 2007

By: /chalin a. smith/

SMITH PATENT CONSULTING, LLC
3309 Duke Street
Alexandria, VA 22314

Name: Chalin A. Smith
Title: Attorney for Applicant
Registration No. 41,569

Tel: 703-549-7691
Fax: 703-549-7692

CUSTOMER NUMBER 31496

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. SBL-001US		SERIAL NO. 09/892,613	
				APPLICANT Shawn Shui-on LEUNG			
				FILING DATE June 27, 2001		GROUP 1643	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY/APPLICANT	CLASS	SUBCLASS	Translation Yes No	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Fiona ADAIR, "Immunogenicity: The Last Hurdle for Clinically Successful Therapeutic Antibodies", <i>BioPharm</i> , pp. 42-46 (October 2000).							
Man Sung CO et al., "Humanized Antibodies for Antiviral Therapy", <i>PNAS USA</i> , Vol. 88: 2869-2973 (April 1991).							
Elvin A. KABAT et al., "Identical V Region Amino Acid Sequences and Segment of Sequences in Antibodies of Different Specificities", <i>Journal of Immunology</i> , Vol. 147 (5): 1709-1719 (September 1991).							
Eduardo A. PADLAN, "Anatomy of the Antibody Molecule", <i>Molecular Immunology</i> , vol 31 (3): 169-217 (1994).							
Tai Te WU et al., "Possible Use of Similar Framework Region Amino Acid Sequences Between Human and Mouse Immunoglobulins for Humanizing Mouse Antibodies", <i>Molecular Immunology</i> , Vol. 29 (9): 1141-1146 (1992).							
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.